

---

# A MOMENT IN MARKETS – THE LONG-AWAITED RETURN OF THE EMERGING MARKETS RISK PREMIUM?

Mobeen Tahir – Director, Research  
03 Feb 2021

The notion of an emerging markets (EM) risk premium exists to compensate investors for taking the risk of investing in economies with relatively more uncertain but potentially higher growth. Does this premium exist in equity markets? It depends on how far back you look. Since the turn of the millennium, emerging markets have outpaced world equities by around 2.2% per annum<sup>1</sup>. But the story so far appears to be split into two halves. EM equities outperformed world equities in the first decade but lagged in the second. Investors may choose to dissect periods of relative performance as they like. The key learning outcome is that the outperformance has not always been steady.

It is therefore pertinent to ask whether the year ahead will be conducive for EM equities. Were the strong relative returns of EM equities in January ephemeral or was the performance a harbinger of the outlook for the rest of the year? There are no certainties when it comes to the future. There are, however, existing tailwinds which can give investors comfort in overweighting the EM risk premium within an equity portfolio this year.

Monetary and fiscal accommodation from major central banks around the world is expected to persist this year. This will continue to lend buoyancy to risk assets across the spectrum. A vaccine-led end to the pandemic promises to accelerate the economic recovery this year – something that will be welcomed by equity markets across the board. Many EM economies hit hard by the pandemic like India, Brazil, Mexico, and South Korea will be seeking to rebuild their domestic economies. Others that have fared better in suppressing the pandemic like China, Taiwan, and South Korea will be looking to their trading partners in America and Europe to bring their economic recovery on track.

But monetary and fiscal accommodation in the US also means low to negative real Treasury yields and a weak US dollar. This could continue to be the case until the US economy is strong enough for policy tightening to become justifiable. Is it possible for this scenario to unfold as early as this year? If not, negative real yields may push more capital towards emerging markets while a weak dollar will make it easier for emerging markets to service their dollar-denominated debt. Both are very good outcomes for EM equities.

And how important is China going to be? The country wields a weight of over 39%<sup>2</sup> in the MSCI Emerging Markets Index making the country's fortunes inextricably intertwined with broader EM indices. Its new 5-year plan for 2021-2025 sets out a 'dual circulation' policy built on domestic growth as well as international trade. China's economic growth last year contrasts sharply with other major economies as the country was able to pull itself out of recovery mode very promptly. Its recent investment and trade deals with

the European Union as well as partners in the Asia-Pacific region also reaffirm its global ambitions.

And how will US foreign policy shape up under the Biden administration, particularly on the trade front, and especially towards China? While it would be naïve to assume that economic and technological rivalry between China and the US is going to disappear, it might be reasonable to expect the relationship to be less confrontational. The bottomline is that asset markets abhor uncertainty and welcome clarity. A stable and less uncertain relation between the two largest economies in the world will bode well for EM assets.

[A moment in markets – Navigating equity markets in the year ahead](#) introduced a possible framework for investors to build an equity portfolio this year. The approach was built on three key components: a core made of quality; diversity through cyclicals; and growth through thematic exposures. An emerging market overweight sits within the ‘diversity through cyclicals’ basket being a segment of global equity markets that not only offers diversity but stands to benefit from an economic upswing.

#### Sources

<sup>1</sup> Bloomberg. Data as of 02 February 2021. Emerging market equities refer to the MSCI Emerging Markets Index in USD and world equities refer to the MSCI World Index in USD.

<sup>2</sup> MSCI as of 02 February 2021.

#### Related products

- + CHIC/CHIN/CHIP ICBCCS wisdomTree S&P China 500 UCITS ETF Class B - USD
- + [DGSE/DGSD WisdomTree Emerging Markets SmallCap Dividend UCITS ETF](#)
- + [DEM/DEMD WisdomTree Emerging Markets Equity Income UCITS ETF](#)

View the online version of this article [here](#).

Important Information

**Marketing communications issued in the European Economic Area (“EEA”):** This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

**Marketing communications issued in jurisdictions outside of the EEA:** This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

**For professional clients only.** The information contained in this document is for your general information only and is neither an offer for sale nor a solicitation of an offer to buy securities or shares. This document should not be used as the basis for any investment decision. Investments may go up or down in value and you may lose some or all of the amount invested. Past performance is not necessarily a guide to future performance. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

The application of regulations and tax laws can often lead to a number of different interpretations. Any views or opinions expressed in this communication represent the views of WisdomTree and should not be construed as regulatory, tax or legal advice. WisdomTree makes no warranty or representation as to the accuracy of any of the views or opinions expressed in this communication. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares or securities in the United States or any province or territory thereof. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States.

Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.